Comparing Lipocine (NASDAQ:LPCN) & Critical Outcome Technologies (OTCMKTS:COTQF)

Lipocine (NASDAQ:LPCN) and Critical Outcome Technologies (OTCMKTS:COTQF) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

9.1% of Lipocine shares are held by institutional investors. 6.4% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Lipocine and Critical Outcome Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1	1	0	1	2.33
Critical Outcome Technologies	0	0	0	0	0.00

Lipocine presently has a consensus target price of $15.00, suggesting a potential upside of 507.29%. Given Lipocine’s stronger consensus rating and higher probable upside, equities analysts plainly believe Lipocine is more favorable than Critical Outcome Technologies.

Valuation & Earnings

This table compares Lipocine and Critical Outcome Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98 million	10.28	-$9.63 million	($1.88)	-1.31
Critical Outcome Technologies	N/A	N/A	N/A	N/A	N/A

Critical Outcome Technologies has lower revenue, but higher earnings than Lipocine.

Profitability

This table compares Lipocine and Critical Outcome Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
Critical Outcome Technologies	N/A	N/A	N/A

Summary

Lipocine beats Critical Outcome Technologies on 6 of the 9 factors compared between the two stocks.

About Lipocine

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

About Critical Outcome Technologies

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.